Drug Patents owned by Abbvie Inc
1. Drug name - MAVYRET
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8648037 | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(9 years from now) | |
| US8937150 | ABBVIE INC | Anti-viral compounds |
May, 2032
(9 years from now) | |
| USRE48923 | ABBVIE INC | Crystal forms |
May, 2035
(12 years from now) | |
| US9321807 | ABBVIE INC | Crystal forms |
Jun, 2035
(12 years from now) | |
| CN103819537A | ABBVIE INC | Anti-Viral Compounds |
May, 2017
(5 years ago) | |
| CN104193729A | ABBVIE INC | Antiviral Compound |
Sep, 2017
(5 years ago) | |
| CN106986861A | ABBVIE INC | Antiviral Compound |
Jun, 2020
(2 years ago) | |
| CN103819459B | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN103819459A | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN103172620A | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103172620B | ABBVIE INC | Antiviral Compound |
Jun, 2030
(7 years from now) | |
| CN102333772A | ABBVIE INC | Anti-Viral Compounds |
Jun, 2030
(7 years from now) | |
| CN102333772B | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103209686A | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103209686B | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103209703A | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| CN104829688A | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| CN104829688B | ABBVIE INC | Macrocyclic Proline-Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| CN103209703B | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| CN103153988B | ABBVIE INC | Antiviral Compound |
Oct, 2031
(9 years from now) | |
| CN103153988A | ABBVIE INC | Anti-Viral Compounds |
Oct, 2031
(9 years from now) | |
| CN103354808A | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103354808B | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103596941A | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| CN103596941B | ABBVIE INC | Antiviral Compounds |
Feb, 2032
(9 years from now) | |
| CN108350016A | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| CN108350016B | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| EP2954892B1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2954892A1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2455376A1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2337781B1 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2628481B1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2628481A1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2337781A2 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2455376B1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2368890B1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890A1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890B9 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2579854B1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854B2 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854A1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2618831B1 | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| EP2618831A1 | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| EP2618831A4 | ABBVIE INC | Macrocyclic Proline Derived Hcv Serine Protease Inhibitors |
Sep, 2031
(8 years from now) | |
| EP2692346A1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2692346B1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2678334B1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| EP2678334A1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039754 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US10028937 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9586978 | ABBVIE INC | Anti-viral compounds |
Nov, 2030
(8 years from now) | |
|
US10028937
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(8 years from now) | |
|
US10039754
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(8 years from now) | |
|
US9586978
(Pediatric) | ABBVIE INC | Anti-viral compounds |
May, 2031
(8 years from now) | |
|
US8648037
(Pediatric) | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(9 years from now) | |
|
US8937150
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Nov, 2032
(10 years from now) | |
| US10286029 | ABBVIE INC | Method for treating HCV |
Mar, 2034
(11 years from now) | |
|
US10286029
(Pediatric) | ABBVIE INC | Method for treating HCV |
Sep, 2034
(11 years from now) | |
|
USRE48923
(Pediatric) | ABBVIE INC | Crystal forms |
Nov, 2035
(13 years from now) | |
|
US9321807
(Pediatric) | ABBVIE INC | Crystal forms |
Dec, 2035
(13 years from now) | |
| US11246866 | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(13 years from now) | |
|
US11246866
(Pediatric) | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(14 years from now) | |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG;40MG | TABLET;ORAL | Prescription |
2. Drug name - ORIAHNN (COPACKAGED)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(1 year, 9 months from now) | |
| US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(1 year, 11 months from now) | |
| CN100424078C | ABBVIE INC | As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives |
Jul, 2024
(1 year, 9 months from now) | |
| CN1819829A | ABBVIE INC | As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives |
Jul, 2024
(1 year, 9 months from now) | |
| IN200600072P1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| IN312234B | ABBVIE INC | Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| EP1646389A1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| EP1646389B1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10881659 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) | |
| US11045470 | ABBVIE INC | Methods of treating heavy menstrual bleeding |
Mar, 2034
(11 years from now) | |
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | CAPSULE;ORAL | Prescription |
3. Drug name - ORILISSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(1 year, 9 months from now) | |
| US7056927 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(1 year, 11 months from now) | |
| CN100424078C | ABBVIE INC | As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives |
Jul, 2024
(1 year, 9 months from now) | |
| CN1819829A | ABBVIE INC | As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives |
Jul, 2024
(1 year, 9 months from now) | |
| IN200600072P1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| IN312234B | ABBVIE INC | Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| EP1646389A1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| EP1646389B1 | ABBVIE INC | Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists |
Jul, 2024
(1 year, 9 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7176211 | ABBVIE INC | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(1 year, 9 months from now) | |
| US10682351 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
| US10537572 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
Drugs and Companies using ELAGOLIX SODIUM ingredient
Treatment: Management of moderate to severe pain associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 150MG BASE | TABLET;ORAL | Prescription |
| EQ 200MG BASE | TABLET;ORAL | Prescription |
4. Drug name - QULIPTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(9 years from now) | |
| US8754096 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) | |
| US9850246 | ABBVIE INC | Process for making CGRP receptor antagonists |
Mar, 2033
(10 years from now) | |
| CN103328478A | ABBVIE INC | Piperidones Carboxamide Indane Cgrp Receptor Antagonist |
Nov, 2031
(9 years from now) | |
| CN103328478B | ABBVIE INC | Piperidone Carboxamide Nitrogen Mixed Indene Into Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| IN201303390P4 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| IN289826B | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2821407B1 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2638042A1 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2821407A1 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2638042B1 | ABBVIE INC | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2849568B1 | ABBVIE INC | Process For Making Cgrp Receptor Antagonists |
Mar, 2033
(10 years from now) | |
| EP2849568A4 | ABBVIE INC | Process For Making Cgrp Receptor Antagonists |
Mar, 2033
(10 years from now) | |
| EP2849568A1 | ABBVIE INC | Process For Making Cgrp Receptor Antagonists |
Mar, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE INC | Tablet formulation for CGRP active compounds |
Jan, 2035
(12 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
| 30MG | TABLET;ORAL | Prescription |
| 60MG | TABLET;ORAL | Prescription |
5. Drug name - RINVOQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE47221 | ABBVIE INC | Tricyclic compounds |
Dec, 2030
(8 years from now) | |
| US8962629 | ABBVIE INC | Tricyclic compounds |
Jan, 2031
(8 years from now) | |
| US10981923 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US11186584 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US9951080 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| CN102118968A | ABBVIE INC | Novel Tricyclic Compounds |
Sep, 2015
(7 years ago) | |
| CN104592231A | ABBVIE INC | Novel Tricyclic Compounds |
Jan, 2019
(3 years ago) | |
| CN102711476A | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN109053742B | ABBVIE INC | Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN104370909A | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN104370909B | ABBVIE INC | Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN109053742A | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN102711476B | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| IN292307B | ABBVIE INC | Novel Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| IN201100195P1 | ABBVIE INC | Novel Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| EP2299821A4 | ABBVIE INC | Novel Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| EP2299821A1 | ABBVIE INC | Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| EP2299821B1 | ABBVIE INC | Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| EP2506716A1 | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| EP2506716A4 | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| EP2506716B1 | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10995095 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10344036 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US11198697 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10597400 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10519164 | ABBVIE INC | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10981924 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10550126 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US9963459 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10730883 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
Drugs and Companies using UPADACITINIB ingredient
Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 15MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 30MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
6. Drug name - TECHNIVIE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
| CN103819537A | ABBVIE INC | Anti-Viral Compounds |
May, 2017
(5 years ago) | |
| CN104193729A | ABBVIE INC | Antiviral Compound |
Sep, 2017
(5 years ago) | |
| CN106986861A | ABBVIE INC | Antiviral Compound |
Jun, 2020
(2 years ago) | |
| CN103819459B | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN103819459A | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN102641271B | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Aug, 2021
(1 year, 1 month ago) | |
| CN102641271A | ABBVIE INC | Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound |
Aug, 2021
(1 year, 1 month ago) | |
| CN101775017B | ABBVIE INC | Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| CN101775017A | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| CN103172620A | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103172620B | ABBVIE INC | Antiviral Compound |
Jun, 2030
(7 years from now) | |
| CN102333772A | ABBVIE INC | Anti-Viral Compounds |
Jun, 2030
(7 years from now) | |
| CN102333772B | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103209686A | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103209686B | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103153988B | ABBVIE INC | Antiviral Compound |
Oct, 2031
(9 years from now) | |
| CN103153988A | ABBVIE INC | Anti-Viral Compounds |
Oct, 2031
(9 years from now) | |
| CN103354808A | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103354808B | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103596941A | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| CN103596941B | ABBVIE INC | Antiviral Compounds |
Feb, 2032
(9 years from now) | |
| CN108350016A | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| CN108350016B | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| IN287227B | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| IN200907222P1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2954892B1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2954892A1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2468285B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468285A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468286A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2805726B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468287B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2805726A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468286B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468287A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2340029A4 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2340029A2 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2340029B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2455376A1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2337781B1 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2628481B1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2628481A1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2337781A2 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2455376B1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2368890B1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890A1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890B9 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2579854B1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854B2 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854A1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2692346A1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2692346B1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2678334B1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| EP2678334A1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 10 months from now) | |
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 10 months from now) | |
|
US8268349
(Pediatric) | ABBVIE INC | Solid pharmaceutical dosage form |
Feb, 2025
(2 years from now) | |
|
US8399015
(Pediatric) | ABBVIE INC | Solid pharmaceutical dosage form |
Feb, 2025
(2 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
|
US8420596
(Pediatric) | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(9 years from now) | |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 12.5MG;75MG;50MG | TABLET;ORAL | Discontinued |
7. Drug name - VENCLEXTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8546399 | ABBVIE INC | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(8 years from now) | |
| US10730873 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(9 years from now) | |
| US8722657 | ABBVIE INC | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(9 years from now) | |
| CN103328474A | ABBVIE INC | Salt And Crystalline Cell Apoptosis Inducing Agent |
Apr, 2018
(4 years ago) | |
| CN104906100A | ABBVIE INC | Cell Procedure Death Inducing Medicine Preparation For Treating Cancer And Immune And Autoimmune Disease |
Sep, 2019
(3 years ago) | |
| CN109897038A | ABBVIE INC | For Programmed Cell Death-Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| CN102448959B | ABBVIE INC | Cell Procedure Death Inducing Medicine Preparation For Treating Cancer And Immune And Autoimmune Disease |
May, 2030
(7 years from now) | |
| CN102448959A | ABBVIE INC | Apoptosis-Inducing Agents For Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| CN104876927B | ABBVIE INC | A Programmed Cell Death Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| CN104876927A | ABBVIE INC | For The Treatment Of Cancer And Immune And Autoimmune Diseases Of Programmed Cell Death Inducing Agent |
May, 2030
(7 years from now) | |
| CN109897038B | ABBVIE INC | Cell Programmed Death-Inducing Agent For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| CN103153993B | ABBVIE INC | Cell Procedure Disease Death Inducing Agent For Treating Cancer And Immune And Autoimmune |
Nov, 2030
(8 years from now) | |
| CN103153993A | ABBVIE INC | Cell Procedure Disease Death Inducing Agent For Treating Cancer And Immune And Autoimmune |
Nov, 2030
(8 years from now) | |
| EP2435432B1 | ABBVIE INC | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| EP2435432A2 | ABBVIE INC | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases |
May, 2030
(7 years from now) | |
| EP2576546A1 | ABBVIE INC | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases |
Nov, 2030
(8 years from now) | |
| EP2576546B1 | ABBVIE INC | Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases |
Nov, 2030
(8 years from now) | |
| EP2643322A1 | ABBVIE INC | Salts And Crystalline Forms Of An Apoptosis-Inducing Agent |
Nov, 2031
(9 years from now) | |
| EP2643322B1 | ABBVIE INC | Salts And Crystalline Forms Of An Apoptosis-Inducing Agent |
Nov, 2031
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174982 | ABBVIE INC | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(7 years from now) | |
| US9539251 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) | |
| US11110087 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(10 years from now) | |
| US10993942 | ABBVIE INC | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(10 years from now) | |
Drugs and Companies using VENETOCLAX ingredient
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnosed acute myeloid leukemia (aml) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
| 50MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
8. Drug name - VIEKIRA PAK (COPACKAGED)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Sep, 2028
(5 years from now) | |
| US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(6 years from now) | |
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
| CN103819537A | ABBVIE INC | Anti-Viral Compounds |
May, 2017
(5 years ago) | |
| CN104628655A | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Jul, 2017
(5 years ago) | |
| CN104193729A | ABBVIE INC | Antiviral Compound |
Sep, 2017
(5 years ago) | |
| CN104628654A | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Oct, 2017
(4 years ago) | |
| CN106986861A | ABBVIE INC | Antiviral Compound |
Jun, 2020
(2 years ago) | |
| CN103819459B | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN103819459A | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN102641271B | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Aug, 2021
(1 year, 1 month ago) | |
| CN102641271A | ABBVIE INC | Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound |
Aug, 2021
(1 year, 1 month ago) | |
| CN102746240A | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Aug, 2021
(1 year, 1 month ago) | |
| CN102746240B | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Aug, 2021
(1 year, 1 month ago) | |
| CN101842360B | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Sep, 2028
(5 years from now) | |
| CN101842360A | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| CN101775017B | ABBVIE INC | Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| CN101775017A | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| CN103172620A | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103172620B | ABBVIE INC | Antiviral Compound |
Jun, 2030
(7 years from now) | |
| CN102333772A | ABBVIE INC | Anti-Viral Compounds |
Jun, 2030
(7 years from now) | |
| CN102333772B | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103209686A | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103209686B | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103153988B | ABBVIE INC | Antiviral Compound |
Oct, 2031
(9 years from now) | |
| CN103153988A | ABBVIE INC | Anti-Viral Compounds |
Oct, 2031
(9 years from now) | |
| CN103354808A | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103354808B | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103596941A | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| CN103596941B | ABBVIE INC | Antiviral Compounds |
Feb, 2032
(9 years from now) | |
| CN108350016A | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| CN108350016B | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| IN287227B | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| IN200907222P1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2954892B1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2954892A1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2639226B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2368882B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2639226A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2368882A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2468285B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468285A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468286A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2805726B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468287B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2805726A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468286B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468287A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2340029A4 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2340029A2 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2203431B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Jan, 2030
(7 years from now) | |
| EP2203431A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Jan, 2030
(7 years from now) | |
| EP2340029B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2455376A1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2337781B1 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2628481B1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2628481A1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2337781A2 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2455376B1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2368890B1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890A1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890B9 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2579854B1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854B2 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854A1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2692346A1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2692346B1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2678334B1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| EP2678334A1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 10 months from now) | |
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 10 months from now) | |
| US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(6 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
| US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US9629841 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(11 years from now) | |
| US10201542 | ABBVIE INC | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(11 years from now) | |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 250MG BASE;12.5MG, 75MG, 50MG | TABLET;ORAL | Discontinued |
9. Drug name - VIEKIRA XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE INC | Anti-infective agents and uses thereof |
Sep, 2028
(5 years from now) | |
| US8188104 | ABBVIE INC | Anti-infective agents and uses thereof |
May, 2029
(6 years from now) | |
| US8642538 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(6 years from now) | |
| US8420596 | ABBVIE INC | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(8 years from now) | |
| US8691938 | ABBVIE INC | Anti-viral compounds |
Apr, 2032
(9 years from now) | |
| CN103819537A | ABBVIE INC | Anti-Viral Compounds |
May, 2017
(5 years ago) | |
| CN104628655A | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Jul, 2017
(5 years ago) | |
| CN104193729A | ABBVIE INC | Antiviral Compound |
Sep, 2017
(5 years ago) | |
| CN104628654A | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Oct, 2017
(4 years ago) | |
| CN106986861A | ABBVIE INC | Antiviral Compound |
Jun, 2020
(2 years ago) | |
| CN103819459B | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN103819459A | ABBVIE INC | Antiviral Compound |
May, 2021
(1 year, 4 months ago) | |
| CN102641271B | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Aug, 2021
(1 year, 1 month ago) | |
| CN102641271A | ABBVIE INC | Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound |
Aug, 2021
(1 year, 1 month ago) | |
| CN102746240A | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Aug, 2021
(1 year, 1 month ago) | |
| CN102746240B | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Aug, 2021
(1 year, 1 month ago) | |
| CN101842360B | ABBVIE INC | Anti-Infection Pyridine And Application Thereof |
Sep, 2028
(5 years from now) | |
| CN101842360A | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| CN101775017B | ABBVIE INC | Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| CN101775017A | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| CN103172620A | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103172620B | ABBVIE INC | Antiviral Compound |
Jun, 2030
(7 years from now) | |
| CN102333772A | ABBVIE INC | Anti-Viral Compounds |
Jun, 2030
(7 years from now) | |
| CN102333772B | ABBVIE INC | Antiviral Composition |
Jun, 2030
(7 years from now) | |
| CN103209686A | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103209686B | ABBVIE INC | Solid Composition |
Jun, 2031
(8 years from now) | |
| CN103153988B | ABBVIE INC | Antiviral Compound |
Oct, 2031
(9 years from now) | |
| CN103153988A | ABBVIE INC | Anti-Viral Compounds |
Oct, 2031
(9 years from now) | |
| CN103354808A | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103354808B | ABBVIE INC | Antiviral Compound |
Dec, 2031
(9 years from now) | |
| CN103596941A | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| CN103596941B | ABBVIE INC | Antiviral Compounds |
Feb, 2032
(9 years from now) | |
| CN108350016A | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| CN108350016B | ABBVIE INC | Antiviral Tetrahydrofuran Derivatives |
Sep, 2036
(13 years from now) | |
| IN287227B | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| IN200907222P1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2954892B1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2954892A1 | ABBVIE INC | Solid Compositions |
Jun, 2020
(2 years ago) | |
| EP2639226B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2368882B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2639226A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2368882A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Sep, 2028
(5 years from now) | |
| EP2468285B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468285A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468286A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2805726B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468287B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2805726A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468286B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2468287A1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Sep, 2029
(6 years from now) | |
| EP2340029A4 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2340029A2 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2203431B1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Jan, 2030
(7 years from now) | |
| EP2203431A1 | ABBVIE INC | Anti-Infective Pyrimidines And Uses Thereof |
Jan, 2030
(7 years from now) | |
| EP2340029B1 | ABBVIE INC | Macrocyclic Hepatitis C Serine Protease Inhibitors |
Jan, 2030
(7 years from now) | |
| EP2455376A1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2337781B1 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2628481B1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2628481A1 | ABBVIE INC | Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv |
Jun, 2030
(7 years from now) | |
| EP2337781A2 | ABBVIE INC | Anti-Viral Compounds To Treat Hcv Infection |
Jun, 2030
(7 years from now) | |
| EP2455376B1 | ABBVIE INC | Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv) |
Jun, 2030
(7 years from now) | |
| EP2368890B1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890A1 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2368890B9 | ABBVIE INC | Hepatitis C Virus Inhibitors |
Jun, 2030
(7 years from now) | |
| EP2579854B1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854B2 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2579854A1 | ABBVIE INC | Solid Compositions |
Jun, 2031
(8 years from now) | |
| EP2692346A1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2692346B1 | ABBVIE INC | An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative |
Oct, 2031
(9 years from now) | |
| EP2678334B1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| EP2678334A1 | ABBVIE INC | Anti-Viral Compounds |
Feb, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 10 months from now) | |
| US8399015 | ABBVIE INC | Solid pharmaceutical dosage form |
Aug, 2024
(1 year, 10 months from now) | |
| US9139536 | ABBVIE INC | Anti-infective agents and uses thereof |
Nov, 2028
(6 years from now) | |
| US9006387 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9044480 | ABBVIE INC | Compositions and methods for treating HCV |
Apr, 2031
(8 years from now) | |
| US8686026 | ABBVIE INC | Solid compositions |
Jun, 2031
(8 years from now) | |
| US10201541 | ABBVIE INC | Compositions and methods for treating HCV |
May, 2032
(9 years from now) | |
| US10201584 | ABBVIE INC | Compositions and methods for treating HCV |
May, 2032
(9 years from now) | |
| US8466159 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8680106 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8492386 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US8685984 | ABBVIE INC | Methods for treating HCV |
Sep, 2032
(9 years from now) | |
| US9333204 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(12 years from now) | |
| US9744170 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(12 years from now) | |
| US10105365 | ABBVIE INC | Solid antiviral dosage forms |
Jan, 2035
(12 years from now) | |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprevir/ritonavir fixed dose combination; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 200MG BASE;8.33MG;50MG;33.33MG | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
10. Drug name - VUITY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610518 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(16 years from now) | |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 1.25% | SOLUTION;OPHTHALMIC | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.